Pluripotent stem cells (PSCs) may provide a potential source of haematopoietic stem/progenitor cells (HSPCs) for transplantation; however, unknown molecular barriers prevent the self-renewal of PSC-HSPCs. Using two-step differentiation, human embryonic stem cells (hESCs) differentiated in vitro into multipotent haematopoietic cells that had the CD34 + CD38 −/lo CD90 + CD45 + GPI-80 + fetal liver (FL) HSPC immunophenotype, but exhibited poor expansion potential and engraftment ability. Transcriptome analysis of immunophenotypic hESC-HSPCs revealed that, despite their molecular resemblance to FL-HSPCs, medial HOXA genes remained suppressed. Knockdown of HOXA7 disrupted FL-HSPC function and caused transcriptome dysregulation that resembled hESC-derived progenitors. Overexpression of medial HOXA genes prolonged FL-HSPC maintenance but was insufficient to confer self-renewal to hESC-HSPCs. Stimulation of retinoic acid signalling during endothelial-to-haematopoietic transition induced the HOXA cluster and other HSC/definitive haemogenic endothelium genes, and prolonged HSPC maintenance in culture. Thus, medial HOXA gene expression induced by retinoic acid signalling marks the establishment of the definitive HSPC fate and controls HSPC identity and function.
Haematopoietic stem cells (HSCs) regenerate the blood system on transplantation, and can therefore cure inherited and acquired blood diseases. However, lack of HLA (human leukocyte antigen)-matched bone marrow or cord blood donors limits their therapeutic use 1 . Generation of HSCs from human embryonic stem cells (hESCs) or induced pluripotent stem cells (PSCs) could provide alternative HSC sources. Recent studies used transcription factor reprogramming to convert fibroblasts or mature blood cells [2] [3] [4] to haematopoietic cells possessing some properties of HSCs. Despite these promising approaches, clinical application of in vitro-generated HSCs remains unachieved.
Although hESCs can differentiate into most blood lineages 5 , efforts to produce engraftable HSCs have failed 6 . The molecular barriers preventing HSC generation in vitro are poorly understood owing to lack of studies comparing candidate HSCs from PSC cultures and human conceptus that match by immunophenotype and developmental stage. During embryogenesis, haematopoiesis starts in the yolk sac by the generation of two distinct waves of myelo-erythroid progenitors (primitive and transient definitive) that can be distinguished by the specific globins expressed in their progeny 7 . These progenitors lack self-renewal ability and robust lymphoid potential 8, 9 . Definitive HSCs possessing these properties emerge in the third haematopoietic wave from specialized haemogenic endothelium in major arteries in the AGM (aorta-gonadmesonephros) region, yolk sac, placenta and vitelline and umbilical vessels 10 . Human haemogenic endothelial cells express CD34 and CD31 11 and upregulate CD43 on haematopoietic commitment 12, 13 , whereas HSCs also co-express CD45 (pan-haematopoietic), CD90 (HSC, endothelium) and GPI-80 (human fetal HSCs 14 ), and typically have low CD38 expression (lineage commitment/HSC activation). Haematopoietic differentiation of mouse and human ESCs mirrors embryonic haematopoiesis 8, 15 and recapitulates mesoderm and haemato-vascular commitment 16, 17 followed by waves of primitive and definitive erythropoiesis 18, 19 . However, hESC-derived haematopoietic cells lack reconstitution ability 6, 20, 21 and full lymphoid and adult-type erythroid potential 22, 23 , resembling yolk sac-derived lineage-restricted progenitors 24 . A long-standing goal has been to A R T I C L E S identify regulatory cues and molecular landmarks that distinguish the definitive HSC fate from the short-lived embryonic progenitors.
We used a two-step hESC differentiation to generate HSPCs with human fetal HSC surface phenotype (CD45 + CD34 + CD38 −/lo CD90 + GPI-80 + ). Molecular profiling showed remarkable resemblance of hESC-HSPCs to FL-HSPCs, yet revealed distinct differences in HSC regulatory programs, including the HOXA genes. Knockdown and overexpression studies revealed that medial HOXA genes, in particular HOXA7, govern definitive HSPC identity and function. Rescue of retinoic acid (RA) signalling during endothelialto-haematopoietic transition induced medial HOXA genes and the definitive haematopoietic program in hESC-HSPCs. These studies uncover regulatory programs that distinguish human definitive HSC lineage from embryonic progenitors and offer a blueprint for identifying missing cues required for HSC generation.
RESULTS hESCs generate HSPCs that are unable to engraft
To identify barriers for generating HSCs from PSCs, we compared hESC-derived HSPCs and human fetal HSCs on the basis of immunophenotypic, functional and molecular criteria. Secondtrimester FL-HSCs were used as controls as they are ontologically closer to PSC-derived cells than cord blood or bone marrow. A twostep differentiation protocol was employed to generate haematopoietic cells from H1 hESCs (Fig. 1a ). To promote haemato-vascular differentiation, embryoid bodies (EBs) were cultured with BMP4 (days 4-10), FLT3L and SCF (days 4-14) 25 . Day-14 EBs had generated cells that co-expressed CD34, CD90 and CD43 (Fig. 1b) , but not CD45. To promote the development of haemato-vascular precursors towards HSCs, EB-derived CD34 + cells were plated with TPO, SCF and FLT3L on OP9-M2 stroma, which supports the expansion of multipotent human HSPCs 26 . Two-week OP9-M2 co-culture (EB-OP9) generated cells with CD34 + CD38 −/lo CD90 + CD45 + HSPC immunophenotype ( Fig. 1b ) and some co-expressed the HSC marker GPI-80 ( Fig. 1c ). These data showed that two-step differentiation generates cells with the immunophenotype of human fetal HSCs.
To assess whether the hESC-HSPC maturation culture on OP9-M2 stroma confers functional properties of HSCs, CD34 + cells from EBs (isolated directly or after two-step differentiation), and FL (isolated directly or after 2-week culture) were transplanted into sublethally irradiated NOD-scid IL2Rγ -null (NSG) mice ( Supplementary Fig. 1A ). Human CD45 + chimaerism in bone marrow was measured 12 weeks post-transplantation. Although FL-HSPCs engrafted successfully before or after OP9-M2 culture, hESC-derived cells showed minimal engraftment (Fig. 1d ). Human CD45 + cells in the bone marrow of mice transplanted with FL contained HSPCs ( Supplementary Fig. 1B ), CD19 + B cells, CD3 + T cells and CD13 + or CD66 + myeloid cells, whereas the mice transplanted with hESC-derived cells harboured only rare human myeloid cells (Fig. 1e) . These data show that hESC-HSPCs are severely impaired functionally.
hESC-HSPCs have poor proliferative potential
To understand the functional defects in hESC-HSPCs, hESC-and cultured FL-HSPCs (CD34 + CD38 −/lo CD90 + CD45 + ) were sorted and re-plated on OP9-M2 co-culture to assess their expansion ( Fig. 2a ). Both FL-and hESC-HSPC cultures maintained an immunophenotypic HSPC population 1 week later (Fig. 2b,c) ; however, at 3 weeks, hESC-HSPCs had disappeared (Fig. 2b,c) . BrdU incorporation analysis did not reveal differences in cell cycle between FL-and hESC-HSPCs (Supplementary Fig. 2A ), suggesting that loss of hESC-HSPCs was not due to inability to divide.
hESC-HSPCs also produced fewer clonogenic progenitors on OP9-M2 than FL-HSPCs (Fig. 2d ), although both formed erythroid (BFU-E), granulocyte-macrophage (CFU-GM), macrophage (CFU-M) and mixed myelo-erythroid (CFU-mixed) colonies ( Fig. 2e) . CFU-C potential in EB-OP9 cells was higher in the CD34 + CD38 −/lo CD90 + CD45 + fraction than total CD34 + cells (Supplementary Fig. 2B ), which also showed minimal CFU-C expansion ( Supplementary Fig. 2C ). These data indicate that hESC-derived immunophenotypic HSPCs exhibit poor proliferative potential.
Previous studies documented impaired differentiation of hESCs to adult-type erythroid cells 23 . Colonies from EB CD34 + cells generated erythroid cells that predominantly expressed embryonic ε-globin, whereas fetal γ-globin (HBG1) was low (16.3% of FL levels) and adult β-globin (HBB) nearly undetectable (1.8% of FL levels). However, colonies derived from EB CD34 + cells after 2 weeks on OP9-M2 induced some expression of γ-and β-globins (84.9% and 54.0% of FLderived cells, respectively; Supplementary Fig. 2D ). β-globin induction suggests that hESC-HSPCs can differentiate to adult-type erythroid cells if given adequate maturation time in culture.
T-cell generation is another hallmark of definitive haematopoiesis 27 . Both EB-and FL-derived CD34 + cells generated CD4 and CD8 single-and double-positive T-lymphoid cells in OP9-DL1 culture ( Supplementary Fig. 2E ). These results imply that the main defect in hESC-derived haematopoietic cells is not differentiation, but self-renewal.
Microarray uncovers molecular defects in hESC-HSPCs
To understand the defective self-renewal of hESC-HSPCs, we assessed their relationship to primary human fetal HSPCs using microarray analysis. Gene expression differences were compared between immunophenotypic HSPCs (CD34 + CD38 −/lo CD90 + CD43 + CD45 +/− ) derived from hESCs through EB or two-step differentiation (EB-OP9), and from FL. To assess culture-induced effects, FL-HSPCs were cultured on OP9-M2 for 2 or 5 weeks (FL-OP9). CD34 + CD38 −/lo CD90 + CD43 + cells from early human placenta (PL) were used as a reference for immature human HSPCs ( Supplementary  Table 1 ). Spearman rank coefficient comparisons and hierarchical clustering of samples revealed that FL-HSPCs are more similar to EB-OP9-HSPCs than EB-or PL-HSPCs ( Fig. 3a,b ). EB-OP9-HSPCs were most similar to cultured FL-HSPCs, implying that hESC-HSPC transcriptome was influenced by prolonged culture (Fig. 3a ). Many transcription factors governing the development of definitive HSPCs (SCL/TAL1, GATA2, RUNX1, MYB, ETV6, HOXB4, GFI1B, BCL11A and so on) were expressed in both EB-OP9-HSPCs and FL-HSPCs (Fig. 3c ). These data revealed that EB-OP9-HSPCs are remarkably similar to FL-HSPCs at the molecular level.
To identify co-regulated and differentially expressed programs between samples, K-means clustering and DAVID GO (gene ontology) analysis was performed for all differentially expressed genes (>2-fold, P value <0.05; Supplementary Tables 2 and 3 Figure 1 Two-step culture of hESCs generates immunophenotypic HSPCs that engraft poorly. (a) Culture and isolation strategy for differentiating H1 hESCs to HSPCs. (b) Representative FACS plots from 11 experiments staining for CD34, CD90, CD38, CD45 and CD43 on hESC-derived CD34 + cells isolated from 2-week EBs (EB) and after 2-week maturation culture on OP9-M2 (EB-OP9), compared with cells from second-trimester fetal liver that were isolated directly (FL) or cultured on OP9-M2 (FL-OP9). (c) Representative FACS plots from nine experiments staining for CD38, CD34, CD90 and human fetal HSC self-renewal marker GPI-80 on hESC-and FL-derived cells. (d) Human engraftment in NSG mice with hESC-derived and FL-derived CD34 + cells, before and after OP9-M2 co-culture (individual values and mean are shown; n = 5 EB, n = 4 EB-OP9 and FL, and n = 3 FL-OP9 transplanted mice; statistical significance was calculated using the Wilcoxon rank sum test; see Supplementary Table 7 for statistics source data). (e) Representative FACS plots showing the human CD45 + fraction in the mouse bone marrow 12 weeks post-transplantation. Multi-lineage engraftment is assessed by CD19 and CD3 (B and T lymphoid), and CD66 and CD13 (myeloid) stainings.
showed that OP9-M2 co-culture of EB-derived cells induced many FL-HSPC-associated genes ( Fig. 3d , clusters 2 and 9) that encoded DNA-repair factors and transcriptional regulators ( Fig. 3e ), whereas vascular genes were downregulated ( Fig. 3d , clusters 5 and 6, Fig. 3f ).
K-means clustering also identified genes that remained dysregulated in hESC-HSPCs. The most striking differences were observed in clusters 4 and 8 that contained genes highly expressed in FL-HSPCs but suppressed in hESC-HSPCs and early PL. The most highly enriched GO category was 'Transcription' (Fig. 3d ), which included many HOXA genes. All HOXA genes except for HOXA13 (a regulator of placental vascular labyrinth specification 28 ) were severely suppressed in hESC-derived HSPCs (Fig. 3g HOXA pattern was observed with early PL, raising the hypothesis that medial HOXA gene induction in FL-HSPCs reflects developmental maturation and acquisition of HSC properties. Clusters 4 and 8 also included the HSC regulators HMGN, HLF, PRDM16 and MECOM/EVI1 29, 30 , and the HSC surface markers PROM1/CD133, EMCN and ROBO4 (Fig. 3h ). These analyses demonstrated that the two-step conditioning fails to induce transcriptional regulators highly expressed in FL-HSCs, including HOXA genes.
Medial HOXA genes govern human HSPC function
We next asked whether HOXA gene silencing contributes to the poor self-renewal of hESC-HSPCs. Microarray analysis of human Figure 3 Identification of differentially expressed programs in hESC-and FL-HSPCs. (a) Spearman rank correlation of HSPCs isolated at different stages of development: 3-5-week placenta (CD34 + CD38 −/lo CD90 + CD43 + n = 2), hESC-HSPCs isolated from 2-week EBs (EB, CD34 + CD38 −/lo CD90 + CD43 + n = 2) or after two-step differentiation (EB-OP9, CD34 + CD38 −/lo CD90 + CD43 + CD45 + n = 2), and second-trimester FL isolated freshly (FL, CD34 + CD38 −/lo CD90 + CD45 + n = 3) or after 2 or 5 weeks on OP9-M2 (FL-OP9, CD34 + CD38 −/lo CD90 + CD45) (n = 3 and n = 2, respectively). n represents the number of tissue samples collected from separate specimens per condition. Each replicate was collected from independent experiments and analysed together. FL-HSPC subsets 14 documented expression of several medial HOXA genes in GPI-80 + HSCs and their immediate progeny (Fig. 4a ), and downregulation on differentiation ( Fig. 4b) . As HOXA9 is a known regulator of mouse HSC proliferation 31, 32 , FL-HSPCs were transduced with pLKO.1 shRNA lentiviral vectors targeting HOXA5 or HOXA7 ( Fig. 4c ) to test whether other medial HOXA genes regulate human DLK1  HEMGN  PROM1  HLF  MPL  TERT  PF4  PPBP  ITGA2B  GP1BA  GP1BB  PROS1  THBS1  ITGB3  CDKN1A CDKN2D HBD Supplementary Table 4 and GEO database GSE76685. See Supplementary Table 7 for statistics source data for d,f,i.
HSCs. Knockdown was confirmed using quantitative PCR with reverse transcription (qRT-PCR) 1 week post-transduction ( Fig. 4d and Supplementary Table 6 ). By 2-4 weeks, HOXA5 and HOXA7 shRNA-treated cells were depleted of HSPCs ( Fig. 4e ,f). Cell cycle analysis 1 week post-transduction did not reveal significant differences in BrdU incorporation of HOXA5-or HOXA7 -knockdown HSPCs, ( Supplementary Fig. 3A ), implying that HOXA5-and HOXA7deficient HSPCs can divide, but cannot self-renew. Transplantation of HOXA5 and HOXA7 shRNA-transduced FL-HSPCs into NSG mice ( Fig. 4g ) showed minimal engraftment ( Fig. 4h,i) . These results suggest that both HOXA5 and HOXA7 are necessary for human FL-HSPC expansion in vitro and reconstitution in vivo. HOXA7 showed stronger phenotypes in both assays.
To investigate how HOXA7 regulates human HSCs, pLKO1control-and HOXA7 -shRNA-transduced FL-HSPCs from four different FL tissues were sorted 5 days post-infection and subjected to RNA sequencing ( Fig. 4e ). Five hundred significantly differentially expressed genes (306 upregulated, 194 downregulated, 1.8-fold, P value <0.05) between HOXA7 -knockdown and pLKO1-control HSPCs were identified ( Fig. 4j and Supplementary Table 4 ). Comparison with hESC-HSPC microarray data revealed that 30.1% of the genes upregulated on HOXA7 knockdown were also significantly upregulated in EB-OP9-HSPCs compared with FL-HSPCs, and 34.0% of the downregulated HOXA7 -dependent genes showed low expression in EB-OP9 HSPCs. The shared downregulated genes included HSC regulators HOXA9-10, HLF and HMGN, and HSC surface proteins PROM1/CD133 and MPL (Fig. 4k ). HOXA7 -knockdown HSPCs and EB-OP9-HSPCs also upregulated genes associated with megakaryocytic and erythroid differentiation (Fig. 4l) . The shared upregulated genes also included cell cycle inhibitors CDKN1A (p21Cip1) 33 and CDKN2D (p19Ink4d) 34 , whereas other cell cycle regulators and proliferation markers were unaffected at the messenger RNA level ( Supplementary Fig. 3B ,C). These results imply that HOXA7 activates factors regulating definitive HSC identity and suppresses programs associated with differentiationprimed embryonic progenitors.
HOXA gene overexpression expands FL-HSPCs
We next assessed whether HOXA gene overexpression improves in vitro expansion of FL-HSPCs and hESC-HSPCs. Tetracyclineinducible PNL lentiviral vector 35 ( Supplementary Fig. 4A ), which induced 30-fold overexpression of HOXA5 or HOXA7 in FL-HSPCs ( Supplementary Fig. 4B ), prolonged FL-HSPC maintenance in culture with both HOXA5 and HOXA7 ( Supplementary Fig. 4C ,D). Constitutively active FUGW vector 36 , which resulted in 4-5-fold transgene overexpression, prolonged FL-HSPC maintenance with HOXA7 ( Fig. 5a -e). HSPCs overexpressing HOXA genes showed comparable differentiation ability in colony assays, implying that HOXA5 or HOXA7 expression does not prevent differentiation ( Fig. 5f) .
Although HOXA5 or HOXA7 overexpression promoted FL-HSPC expansion, their overexpression in EB-derived CD34 + cells did not improve hESC-HSPC expansion in vitro ( Fig. 5g-i and Supplementary  Fig. 4E ) or engraftment in vivo ( Fig. 5j,k) . Similar results were observed overexpressing HOXA5, HOXA7 and HOXA9 simultaneously. RNAsequencing of HOXA7 -overexpressing hESC-HSPCs showed that despite the confirmed HOXA7 overexpression (Fig. 5l ), there was minimal change in putative HOXA7 target genes ( Fig. 5m ). Altogether these studies showed that medial HOXA genes promote HSPC expansion when expressed in a correct cellular context.
RA signalling induces HOXA genes in hESC-HSPCs
We next sought for upstream regulators that could specify the definitive HSPC fate and induce HOXA genes in a correct cellular context. Medial HOXA genes are developmentally regulated by RA signalling in other cell types 37, 38 . RA generated by ALDH1A2 (RALDH2) in haemogenic endothelium and its binding to RA receptor alpha (RARA) is necessary for generating HSCs in mouse AGM 39 . Microarray analysis showed robust expression of RARA, and to a lesser extent RARB and RARG in HSPCs at different stages. Notably, RALDH2 was expressed in CD34 + CD38 −/lo CD90 + CD43 + cells in the early placenta, but not in EB. FL-HSPCs did not express RALDH2, consistent with its function in haemogenic endothelium (Fig. 6a ). RALDH1 was expressed in FL-HSPCs but at low levels in both EBand PL-derived cells. These results nominated defective RA signalling during hESC haematopoietic specification as a potential barrier for inducing HOXA genes.
We next asked whether RALDH2 function could be bypassed by administering all-trans retinoic acid (ATRA) or the RARA agonist AM580 40 during hESC differentiation. CD34 + cells were isolated from EBs at 2 weeks and cultured for 6 days on OP9-M2 with or without ATRA (1.0 µM) or AM580 (0.2 µM) ( Fig. 6b ). qRT-PCR analysis showed that treatment of EB-derived CD34 + cells with AM580 or ATRA induced several medial HOXA genes ( Fig. 6c ). AM580 had a more robust effect on HOXA genes and was used for further studies.
Fluorescence-activated cell sorting (FACS) analysis at 6 days of AM580 treatment revealed strong induction of CD38, a known RA target 41 , in hESC-and FL-HSPCs ( Fig. 6d ). Persistent CD90 expression suggested that they had not differentiated. AM580-induced CD38 expression was reversible (Fig. 6d ), and AM580-treated EB CD34 + cells typically retained a higher fraction of CD34 + CD38 −/lo cells and undifferentiated HSPCs after 23-25 days than dimethylsulfoxide (DMSO)-treated controls (Fig. 6e ,f). A concomitant increase was observed with CFU-Cs, in particular with mixed myelo-erythroid colonies ( Supplementary Fig. 5A,B) . These data show that inducing RA signalling in the haemogenic endothelium stage prolongs hESC-HSPC maintenance.
RA signalling promotes definitive haemogenic endothelium and HSC fate
To understand how RA signalling modulates hESC-derived haematovascular precursors, RNA sequencing was performed to define AM580-induced genes in hESC-HSPCs (CD45 + CD34 + CD90 + ). Six days after AM580 treatment, RARB and RARG, known RARA targets 42 , were upregulated (Fig. 7a ). The HOXA cluster was also induced (Fig. 7b,c) , whereas RUNX1, which is expressed in both progenitors and HSCs, showed no difference. Altogether, AM580 induced 408 genes and repressed 562 (twofold, P value <0.05) (Supplementary Table 5 ). AM580-induced genes showed the highest enrichment in GO categories reflecting vasculature development, cell adhesion and migration (Fig. 7d ). These include factors implicated in definitive haemogenic endothelium and HSC Week 4
Week DLK1  HEMGN  PROM1  HLF  MPL  TERT  HBD  HBE1,HBG2  GATA1  GYPB  KLF1  GYPA  SPTA  KEL  PF4  PPBP  ITGA2B  GP1BA  GP1BB  PROS1  THBS1  ITGB3  CDKN1A generation such as CDH5, NOS3 and SOX17 ; Notch ligands and targets DLL4 and HEY2; and HSC surface markers ROBO4, EMCN and PROCR. Another highly enriched category was regulation of transcription, which included several HSC regulators (for example, the HOX cofactor PBX1, MECOM/EVI1, ERG, GFI1, GATA3 and HLF; Fig. 7e ). Analysis of hESC-HSPCs at day 12 of OP9-M2 culture (6 days after AM580 removal) evidenced expression of HOXA, albeit at lower levels, and many vascular factors and HSC regulators ( Supplementary Fig. 6A,B) . Interestingly, many genes upregulated in HOXA7 -knockdown FL-HSPCs and hESC-HSPCs, including cell cycle inhibitors CDKN1A and CDKN2D and erythroid and Table 5 and GEO database GSE76685 for values used to generate graphs in b,e,g-i.
megakaryocytic genes, started to decline in AM580-treated hESC-HSPCs ( Supplementary Fig. 6C ). These data suggest that RARA signalling during endothelial-to-haematopoietic transition induces HOXA genes and other regulators that establish the definitive HSC fate, while suppressing embryonic progenitor programs.
To investigate whether RA signalling induces genes by modulating chromatin accessibility, ATAC sequencing was performed for CD45 + CD34 + CD90 + hESC-HSPCs (DMSO-or AM580-treated for 6 days) and FL-HSPCs. AM580 stimulation increased chromatin accessibility throughout the HOXA cluster (Fig. 7f ). Unbiased analysis of differentially accessible peaks (q value <0.05) between DMSO-and AM580-treated hESC-HSPCs showed that most ATAC sequencing signal was 50-500 kilobases from the transcriptional start site (TSS), which are likely to represent enhancers (Fig. 7g ). GREAT analysis identified vasculature-related categories as top differentially accessible gene groups (Fig. 7h ). The average ATAC sequencing signal around the TSS of AM580-induced genes increased twofold on AM580 treatment (Fig. 7i) , whereas genes repressed on AM580 treatment did not show a difference. These data suggest that RA signalling facilitates chromatin opening in the regulatory regions of the genes it activates.
DISCUSSION
Inability to replicate the microenvironment where HSCs develop has prevented the generation of clinically valuable HSCs from PSCs. However, the molecular barriers underlying the dysfunction of PSC-HSPCs are unknown. Here we document the generation of hESC-HSPCs that possess the immunophenotype of human fetal HSCs and differentiate into adult-type erythroid cells and T-lymphoid cells, but lack self-renewal ability. We pinpointed defective medial HOXA gene activation as a major developmental barrier preventing the establishment of self-renewing HSCs from hESCs, and identified RA signalling during endothelial-to-haematopoietic transition as a key inducer of HOXA genes and HSC fate.
Cells obtained from EBs possessed a surface phenotype of haemogenic endothelium and immature haematopoietic precursors comparable to the early placenta (CD34 + CD38 −/lo CD90 + CD43 + CD45 − GPI-80 − ) 13, 14 . Following culture on HSC-supportive stroma, hESC-HSPCs acquired surface expression of CD45 and GPI-80 14 and a closer molecular resemblance to FL-HSPCs. However, specific developmentally regulated genes, including the HOXA genes, remained silenced in hESC-HSPCs. Low expression of HOXA genes can also be found in published transcriptome analysis of hESC-derived CD34 + cells 2,43-45 , implying that HOXA gene silencing is independent of the differentiation protocol or PSC line used.
HOXA genes are dysregulated in leukaemias 46, 47 and HOXA9 has been previously implicated in mouse fetal HSC self-renewal 32, 48 . Knockout mice for other Hoxa genes have not revealed strong HSC phenotypes, presumably owing to compensation by other Hox genes 49, 50 . Deletion of the entire Hoxa cluster in adult mice severely reduced HSC activity and even Hoxa cluster haploinsufficiency compromised HSC function 51, 52 . HOXA9 overexpression enhanced haematopoietic specification from hESCs, but did not confer HSC function 44 . Our finding that HOXA5 and HOXA7 are critical for in vitro expansion and engraftment of FL-HSPCs, and their overexpression promotes FL-HSPC maintenance, documents a broader requirement for medial HOXA genes in human HSC regulation.
As HOXA7 had the strongest loss-and gain-of-function phenotype, it was chosen for molecular analysis. Many genes dysregulated in HOXA7 -deficient FL-HSPCs were also dysregulated in EB-OP9-HSPCs. Similar to hESC-HSPCs, HOXA7 -deficient FL-HSPCs upregulated embryonic and fetal globins and other erythroid and megakaryocyte differentiation genes, implying that they acquire embryonic progenitor-like identity. Although the cell cycle was unaffected in HOXA7 -deficient FL-HSPCs and hESC-HSPCs, they upregulated cell cycle inhibitors CDKN1A (p21Cip1) and CDKN2D (p19Ink4d). These inhibitors are low in human FL-HSPCs, but become induced after prolonged culture 26 . They are also highly expressed in FL CD34 + CD38 + CD90 − progenitors that proliferate, but cannot self-renew 14 . Thus, upregulation of these CDKNs in haematopoietic cells associates with poor proliferative potential and onset of differentiation.
Although the overexpression of HOXA7, and to a lesser extent HOXA5, improved FL-HSPC maintenance in culture, their overexpression, even together with HOXA9, was insufficient to rescue hESC-HSPC function. HOXA7 overexpression in hESC-HSPCs did not rescue the genes regulated by HOXA7 in FL-HSPCs. The context-dependent regulation of HOXA target genes may depend on their epigenetic state and/or complementary regulatory factors present only in properly specified HSPCs.
We identified RA signalling as an upstream regulator for HOXA genes and the definitive HSPC transcriptional program. RA production by RALDH2 regulates HSC development during endothelial-to-haematopoietic transition in mouse AGM 39 . EBderived haemato-vascular cells showed low RALDH2 expression compared with developmentally matched PL-HSPCs, suggesting that hESC-derived haemato-vascular precursors cannot produce RA. Supplementing RARA agonist to EB-derived haemato-endothelial cells for 6 days induced the expression of medial HOXA genes, and increased chromatin accessibility in the HOXA cluster and other RAinduced genes. Although many RA-regulated vascular genes are not highly expressed in FL-HSPCs, they promote definitive haemogenic endothelium 17 and HSC fate. RA stimulation also induced the HSC regulators MECOM, HLF, GFI1 and GATA3 and the HSC surface markers ROBO4, EMCN and PROCR. Strikingly, RARA stimulation partially suppressed the HOXA7 -controlled differentiation programs and cell cycle inhibitors in hESC-HSPCs. These results suggest that RARA-induced medial HOXA gene activation is critical for HSC fate.
The level of HOXA expression in hESC-HSPCs attenuated after RA stimulation ended, implying that other regulators contribute to maintaining high HOXA expression in HSCs. Moreover, prolonged RA signalling can be detrimental for HSC development and maintenance 53, 54 and RA effects vary with experimental conditions and developmental stage [54] [55] [56] . Therefore, the timing and dosage of RA stimulation must be optimized. Although other genetic programs are needed to impart full self-renewal capacity in HSCs, RA signalling and medial HOXA genes emerge as key regulators governing the patterning of haemogenic endothelium to definitive HSC fate.
METHODS
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M E T H O D S
METHODS Human ESC culture. The human ESC line H1, obtained from WiCell (WA01), was maintained on 50-Gy-irradiated (CF1) murine embryonic fibroblast feeders, in DMEM/F12 medium (Invitrogen) containing 20% knockout serum replacement (Invitrogen), 0.5% penicillin/streptomycin (50 U ml −1 , Invitrogen), 1 mM L-glutamine, 0.5% MEM non-essential amino acids (NEA, Invitrogen), 10 ng ml −1 basic FGF (R&D Systems) and 0.11 mM BME (Invitrogen). hESCs were passaged weekly using 1 mg ml −1 collagenase IV (Invitrogen) in DMEM/F12 for 10 min, detached by gentle pipetting or cell scraper to maintain cells in small clumps, washed twice and split to new 6-well plates containing irradiated CF1 mouse embryonic fibroblasts. Cells were mycoplasma-tested and authenticated by short-term repeat analysis. hESC work was approved by the UCLA Embryonic Stem Cell Research Oversight committee. WA01 is not listed in the ICLAC or NCBI Biosample as a commonly misidentified cell line.
Differentiation of embryoid bodies. hESCs were treated with 0.5 mg ml −1 Dispase (Invitrogen) in DMEM/F12 for 5 min at 37 • C. Clumps were mechanically detached and transferred to low-attachment plates (Corning) in IMDM (Invitrogen), 15% FBS (Hyclone), 1% MEM-NEA, 0.3 µM BME (Invitrogen) and 1% penicillin/streptomycin (100 U ml −1 , Invitrogen)/1 mM L-glutamine (P/S/G). Medium was changed every 2 days and supplemented with 10 ng ml −1 BMP4 (R&D Systems), 50 ng ml −1 FLT3L (Peprotech) and 300 ng ml −1 SCF (Peprotech) at day 4 of EB differentiation. BMP4 was removed from the culture medium at day 12. EBs were collected at 2 weeks and dissociated with 0.25% trypsin-EDTA (Invitrogen) with 2% chick serum (Sigma-Aldrich) for 30 min at 37 • C with periodic agitation and filtered with a 70 µm cell strainer. A step-by-step protocol detailing EB generation and AM580/ATRA treatment can be found at Nature Protocol Exchange 57 .
Human tissue collection. Placenta and fetal liver were de-identified, discarded material obtained from elective termination of first-and second-trimester pregnancies following informed consent. As these tissues are discarded material with no personal identifiers, this research does not constitute research on human subjects. This protocol was reviewed by the UCLA IRB committee, who determined such studies can be performed without further IRB review. Specimen age for this study is denoted as developmental age, 2 weeks less than gestational age, and was determined by ultrasound or estimated by the date of the last menstrual period. Tissues were collected into PBS with 5% FBS (Hyclone), ciprofloxacin HCl (10 ng ml −1 , Sigma), amphotericin B (2.50 µg ml −1 , Invitrogen) and 1% penicillin/streptomycin, transported on ice and processed the same day.
Human tissue processing. Single-cell suspensions were prepared from FL at 14-17 weeks of developmental age. Tissues were mechanically dissociated using scalpels and syringes. Mononuclear cells were enriched on a Ficoll layer according to the manufacturer's protocol (GE Healthcare Biosciences AB) and strained through a 70 µm mesh.
Single cell suspensions were prepared from placenta at 3-5 weeks of developmental age. Tissues were mechanically dissociated and digested in 2.5 U Dispase (Gibco), 90 mg collagenase (Worthington) and 0.075 mg DNase I (Sigma) per gram of tissue for 90 min at 37 • C with agitation. Cells were then filtered through a 70 µm cell strainer.
Selection of CD34 + cells by magnetic beads.
Single-cell suspensions obtained from 2-week EB differentiation cultures, human fetal livers or human placentae were magnetically isolated with anti-CD34 microbeads (Miltenyi Biotech) according to the manufacturer's protocol. 26 were irradiated (20 Gy) and pre-plated (50,000 cells cm −2 ) onto tissueculture-treated wells 24 h before the start of co-culture in OP9 medium (α-MEM (Invitrogen), 20% FBS (Hyclone), P/S/G). Haematopoietic cells derived from hESCs or haematopoietic tissues were plated on a stromal layer in OP9 medium supplemented with SCF (25 ng ml −1 , Peprotech), Flt3 (25 ng ml −1 , Peprotech) and TPO (25 ng ml −1 , Peprotech) (HSC medium). Cells were co-cultured at 37 • C and 5% CO 2 and re-plated or analysed/sorted by flow cytometry every 7-14 days. Half of the HSC medium was replaced every other day. Dead cells were excluded with 7-amino-actinomycin D (7AAD) (BD Biosciences, used at 1:50). Cells were assayed on a BD-LSRII flow cytometer and data were analysed with FlowJo software (Tree Star). Cell sorting was performed using a BD FACS Aria II.
OP9-M2 stromal co-culture for HSPC maturation and expansion. OP9-M2 cells
Methylcellulose colony-forming assays. Myelo-erythroid progenitor potential was assessed on methylcellulose (MethoCult GF + H4435, SCT) supplemented with TPO (10 ng ml −1 , Peprotech), 1% penicillin/streptomycin (100 U ml −1 , Invitrogen) and 1% amphotericin B (2.50 µg ml −1 , Invitrogen). Cultures were incubated at 37 • C and 5% CO 2 for 14-16 days and colonies were scored on the basis of morphological characteristics. Images were taken using an Olympus BX51 microscope with a DP72 camera.
Cytospins. Representative myelo-erythroid colonies from methylcellulose assays were picked and resuspended in PBS with 40% FBS (Hyclone). The cell suspension was cytospun on slides using a Shandon Cytospin 4 (Thermo Electron Corporation) spun at 10g under medium acceleration. Slides were air-dried overnight and stained using May-Grünwald-Giemsa (MGG) stain (Sigma-Aldrich).
Imaging. Bright-field images of individual colonies and images of MGG-stained colonies were taken using the Zeiss Axovert 40 CFL microscope under the ×10 objective with an attached Canon PC 1089 camera at ×4 zoom for a total magnification of ×40.
T-lymphoid differentiation. hESC-or FL-derived CD34 + cells were plated on nonirradiated OP9-DL1 stroma (25,000 cells cm −2 ) in OP9 medium supplemented with SCF (25 ng ml −1 , Peprotech), FLT3L (10 ng ml −1 , Peprotech) and IL-7 (20 ng ml −1 , Peprotech). Cells were lifted and reseeded on OP9-DL1 every week until FACS analysis.
Cell cycle analysis. Cultured cells were pulse-labelled with 10 µM BrdU for 35 min in culture. Cells were sorted for the indicated surface phenotypes and processed according to the FITC-BrdU flow kit (BD) instructions.
RNA isolation, cDNA synthesis and quantitative reverse transcriptase PCR. RNA isolation was performed using the RNeasy Mini kit (Qiagen) with an additional DNase (Qiagen) step using the manufacturer's protocol. cDNAs were prepared using the Quantitech reverse transcription kit (Qiagen) and quantitative polymerase chain reaction (qPCR) for GAPDH, glycophorin A (GYPA), haemoglobin subunit epsilon (HBE), haemoglobin subunit gamma (HBG) and beta globin (HBB) was performed with the LightCycler 480 SYBR Green I Master Mix (Roche) on the Lightcycler 480 (Roche); qPCR for GAPDH and HOXA7 with the SYBR Select Master Mix (Life Technology, LT) using the ViiA 7 Real-Time PCR System (LT); and qPCR for GAPDH, HOXA3, HOXA5, HOXA6 and HOXA9 was performed with the TaqMan Gene Expression Master Mix (LT) and analysed using the ViiA 7 Real-Time PCR System (LT). SYBR Green-compatible primers were obtained from the PrimerBank database or literature 58, 59 . Taqman primers were purchased from LT. Primers were tested against OP9-M2 cDNA to rule out amplification of murine genes, and gDNA or water as negative controls. Primers are presented in Supplementary Table 6 .
Microarray analysis. RNA isolation was performed using RNEasy Mini kit (>50,000 cells) or RNeasy Micro kit (<50,000 cells) (Qiagen) with DNase digestion using the manufacturer's protocol. RNA was amplified by the NuGen amplification kit and hybridized on Affymetrix arrays (Human U133plus2.0 Array). Samples were quantile normalized.
K-means clustering of differentially expressed genes. Pairwise differential expression analysis was performed for the various populations by independently comparing immunophenotypic HSPCs derived from hESCs (EB and EB-OP9), placenta (PL), cultured fetal liver (FL-OP9 2 weeks and FL-OP9 5 weeks), with freshly isolated FL-HSPCs (FL). The following criteria were used to filter probes and identify differentially expressed genes: fold change value of 2 or higher; a P value less than 0.05; probes that are called ' Absent' in all replicates in all samples were excluded; and probes that have an absolute expression level of 50 or less were excluded. The union of all probes that met these criteria was chosen for further analysis, after which normalized expression values, which were replicate-averaged and standardized, were obtained. The standardized expression values were clustered using the K-means method. GO enrichment analysis was performed for genes in the various clusters. Differential expression assessment was performed using the DOI: 10.1038/ncb3354
Limma R package 60 through Bioconductor 61 . To account for multiple comparisons, P values were adjusted using the Benjamini-Hochberg correction method to control the false discovery rate (FDR). A 5% FDR was used as the cutoff. K-means clustering of RMA-normalized, replicate-averaged and standardized expression values was done using Cluster 3.0 software 62 and the resulting clusters were viewed using Java Treeview software 63 .
RNA sequencing analysis. Total RNA from 2,000 to 20,000 sorted cells was extracted using the RNeasy Mini kit (Qiagen) and a library was constructed using Ovation Rna-seq system System v2 (Nugen), followed by KAPA LTP Library Preparation Kit. Libraries were sequenced using HIseq-2000 (Illumina) to obtain single-end 50-bplong reads. Demultiplexing of the reads based on the barcoding was performed using an in-house Unix shell script. Splice junction mapping to the human genome (hg19) was performed using TopHat v2.0.9 or v2.0.14 64 with the parameters -no-coveragesearch -M -T -x 1. Coverage files were created with the Genomecov tool from Bedtools 65 with the parameters -bg -split -ibam. For abundance estimations (FPKMs) the aligned read files were further processed with Cufflinks v2.2.1 66 -compatiblehits-norm -N -u -GTF gencode.v19.annotation.gtf. Assemblies for all samples were merged using Cuffmerge and differential expression was determined using Cuffdiff.
Production of lentiviral shRNA and overexpression vectors.
shRNA experiments were performed with pLKO lentiviral vectors from the TRC library (TRCN000017529 for HOXA5, TRCN000015084 for HOXA7 ) containing puromycin resistance gene. Human HOXA5, HOXA7 and HOXA9 were cloned from human FL full-length cDNA, into either the constitutive pFUGW lentiviral vector (Addgene plasmid no. 14883, from D. Baltimore, California Institute of Technology, Pasadena, California, USA), downstream and in frame with the GFP sequence with the synthetic addition of a P2A sequence between the two ORFs, or the inducible Lentiviral transduction of CD34 + cells. FL-HSPCs were prestimulated for 6-18 h in fresh SFEM culture medium supplemented with 100 ng ml −1 SCF, 100 ng ml −1 TPO and 100 ng ml −1 FLT3L. Wells were treated with 40 µg ml −1 RetroNectin (Takara) and seeded with prestimulated FL-HSPCs in 300 µl SFEM culture medium. Lentivirus (5 µl) was added twice during 24 h incubation. Transduced cells were washed and seeded on OP9-M2 with HSC medium. For shRNA lentiviral vectors, puromycin (1.0 µg ml −1 ) treatment was used for selection of transduced HSPCs and maintained throughout culture. EB-derived CD34 + cells were infected in SFEM for 2 h on a rocking platform at 37 • C and then moved to OP9-M2 co-culture on HSC medium. For overexpression experiments with PNL vectors, doxycycline was added immediately at the start of OP9-M2 culture and maintained at 1 µg ml −1 .
Transplantation into NOD-scid IL2Rγ-null mice. Female NOD-scid IL2Rγ-null (NSG, Jackson Laboratories) mice, 8-12 weeks old, were sublethally irradiated (325 rads) and intra-tibially injected with FL or hESC CD34 + cells in a volume of 35 µl. Mice were transplanted with either 1.2×10 6 EB-derived CD34 + cells (60% CD34 + ) or with 10,000 FL CD34 + cells in 50 µl PBS. A second batch of mice was transplanted with 2.5×10 6 EB-CD34 + -derived cells (25% CD34 + ) or 3×10 6 FL-CD34 + -derived cells (35% CD34 + ) obtained after 2 weeks of culture on OP9-M2.
For shRNA-treated FL cells, 50,000 cells were infected with shRNA lentivirus and expanded on OP9-M2 for 9 days under puromycin selection. Transduced haematopoietic cells were retro-orbitally injected into sublethally irradiated NSG mice.
For engraftment of EB-derived cells overexpressing HOXA genes, 300,000 cells were infected with the indicated lentivirus. After infection, cells were seeded on OP9-M2, expanded for 2 weeks, collected and injected in the right tibia of sublethally irradiated (275 rads) female NSG mice. FL CD34 + cells were injected as a positive control of engraftment.
Mice were euthanized at 10-12 weeks to collect bone marrow. Collected cells were FACS-analysed to evaluate human engraftment (human CD45 and mouse CD45), differentiation into myelo-lymphoid lineages (CD13, CD33, CD66, CD3 or CD19) and preservation of the HSPC compartment (CD34 + , CD38 − , CD90 + ).
All studies and procedures involving mice were approved by the UCLA Animal Research Committee (Protocol 2005-109).
Induction of retinoic acid signalling. ATRA (all-trans retinoic acid, Sigma-Aldrich) was dissolved in DMSO at 25 mM and applied at a final concentration of 1 µM; AM580 (Sigma-Aldrich) was dissolved in DMSO at 10 mM at a final concentration of 0.2 µM; DMSO was used at 1:25,000 final dilution. Treatments were performed on FL-or hESC-derived CD34 + cells in HSC medium. Cells were collected at day 6 for qRT-PCR and RNA sequencing analysis. For longer cultures, RA stimulation media were removed at day 6 from the wells avoiding disruption of the cell layer and replaced with HSC medium with no treatment. Cells were then collected at day 12 reseeded on OP9-M2 for another 12-13 days, and then assayed for HSPC expansion by FACS or colony-forming potential in methylcellulose. A step-by-step protocol detailing EB generation and AM580/ATRA treatment can be found at Nature Protocol Exchange 57 .
ATAC sequencing. Cells (12,000 to 60,000) were sorted in PBS and processed according to the protocol indicated 67 , with minor adjustments. Nuclei were purified by the addition of 250 µl of lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.1%IGEPAL), pelleted and resuspended in the transposition reaction mix (Nextera DNA Library Prep Kit, Illumina) and incubated at 37 • C for 30 min. Transposed DNA was column purified and used for library amplification with custom-made adaptor primers (see Supplementary Table 6 ) using NEBNext High-Fidelity 2x PCR Master Mix (NEB). The amplification was interrupted after five cycles and a SyBR green qPCR was performed with 1/10 of the sample to estimate for each sample the additional number of cycles to perform, before saturation was achieved. Total amplification was between 10 and 15 cycles. Purified libraries were sequenced using HIseq-2000 (Illumina) to obtain paired-end 50-bp-long reads. Demultiplexing of the reads and creation of the fastq files was performed using an in-house Unix shell script. Read mapping to the genome (hg19) was performed using Bowtie2 or v2.2.5 68 with parameters -local -X 2000 -N 1 -no-mixed. The Bamcoverage tool from Deeptools was used to create the coverage .bw files for visualization 69 . Samtools v1.2 was used to remove duplicates and reads aligned to chrM. MACS2 70 was used to call the differentially accessible peaks between the AM580-treated and -untreated EB-derived cells, using the parameters -broadbroad-cutoff 0.1.
Statistics and reproducibility.
Graphs were generated with GraphPad PRISM software. Statistical significance was calculated in R version 3.2.3. Statistical significance was assessed using the Wilcoxon rank sum test for unpaired data sets and the Student's paired t-test for paired data sets. All tests are two-tailed with the exception of that in Fig. 6c , where a one-tailed distribution was used because it is an established fact that RA treatment enhances HOX gene expression. Data sets were considered paired when treatments (that is, DMSO versus AM580 or LKO versus shRNA) were performed in parallel on the same batch of cells (EB) or from the same donor (FL) for the same time periods. Data were considered unpaired when cells from different batches, donors or cell types were compared. The null hypothesis of the medians/means being equal was rejected at α = 0.05 and exact significant P values are shown in each graph. The comparisons to be made were decided a priori with the intention of limiting the overall number of comparisons and are indicated by lines in the figures and adjustments for multiple comparisons would be applied to k > 4 comparisons. To account for multiple comparisons in microarray analysis, P values were adjusted using the Benjamini-Hochberg correction method to control the FDR. The non-parametric Wilcoxon rank sum test is robust to outliers. We tested for differences in sample dispersion using Ansari-Bradley and we could not reject the null hypothesis of equal dispersions. A Satterthwaite's approximation was used to account for unequal variances when using the t-test. The investigators were not blinded to allocation during experiments and outcome assessment. For mouse engraftment studies, the experiments were not randomized, no statistical method was used to predetermine sample size and no animal was excluded from analysis. 
Assess bone marrow engraftment
Week 12
Week 0 B Supplementary Figure 1 Cells were stained for CD45, the myeloid exclusion marker CD14, and T-cell markers CD4 and CD8 (mean +/-SEM shown from n=3 independent experiments. Statistics source data for graphs shown in A, B, C, and E can be found in Supplementary Table 7 . Statistical significance was assessed using the Wilcoxon Rank Sum test for A, B, C, and E. 
